TL;DR - Stryker (NYSE: SYK) Q2 2026 adjusted EPS USD 3.69 (+17.9% YoY), beat consensus of USD 3.49 by 5.7% - Revenue USD 6.6B (+9.4% YoY, organic +9.0%), narrowly beat the USD 6.58B estimate - Shares fell ~5.1% pre-market to USD 330.45 (prior close USD 348.04) despite the beat — investors weigh H2 cyber remediation costs - FY2026 guidance narrowed: adjusted EPS USD 14.95–USD 15.10, organic growth 8.3%–9.3%
Part A: What Was Reported
Stryker Corporation (NYSE: SYK), a medical technology company with a market capitalization of approximately USD 133 billion, reported its Q2 2026 results on July 30, 2026. The company beat analyst estimates on both the top and bottom lines but provided guidance that left investors cautious about the second half.
Q2 2026 Key Metrics
| Metric | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Net Sales | USD 6.6B | USD 6.03B | +9.4% |
| Organic Sales Growth | — | — | +9.0% |
| Adjusted EPS | USD 3.69 | USD 3.13 | +17.9% |
| GAAP EPS | USD 3.30 | USD 2.29 | +44.1% |
| Adjusted Operating Margin | 27.4% | 25.7% | +170 bps |
Segment Breakdown
| Segment | Q2 2026 Revenue | YoY Growth |
|---|---|---|
| MedSurg & Neurotechnology | USD 3.625B | +9.7% |
| Orthopaedics | USD 2.964B | +9.1% |
MedSurg & Neurotechnology — Stryker's largest segment — missed the analyst estimate of approximately USD 3.72B, a detail the market focused on despite the overall revenue beat.
H1 2026 Performance
The first-half figures reflect a year disrupted by a cyberattack. While Q2 organic growth reached 9.0%, H1 organic growth was only 5.0%, reflecting the severe Q1 disruption. H1 2026 net sales came in at USD 12.609B (+6.1% YoY), and operating cash flow improved to USD 1.84B from USD 1.36B in H1 2025.
H1 adjusted EPS of USD 6.29 rose just 5.4% year-over-year (from USD 5.97), undershooting the 17.9% Q2 pace — a clear indication of how much the first quarter weighed on the cumulative picture.
FY2026 Guidance Update
| Metric | New Guidance | Prior Guidance |
|---|---|---|
| Organic Net Sales Growth | 8.3%–9.3% | 8.0%–9.5% |
| Adjusted Diluted EPS | USD 14.95–USD 15.10 | USD 14.90–USD 15.10 |
The floor of the adjusted EPS range was raised by USD 0.05, signaling improved confidence in the recovery. However, the ceiling of the organic growth range was trimmed from 9.5% to 9.3%.
CEO Kevin A. Lobo stated: "We made significant progress in our recovery from the cyber incident, delivering strong growth in sales, earnings per share and operating cash flow in the second quarter."
Part B: The Cyberattack Shadow — Why Shares Fell Despite the Beat
Background: The March 11, 2026 Handala Attack
On March 11, 2026, Stryker became the target of one of the most disruptive cyberattacks ever recorded against a U.S. medical technology company. The attacker was Handala, a hacktivist group assessed by Palo Alto Networks to operate as a front for Iran's Ministry of Intelligence and Security (MOIS).
Using access to Stryker's Microsoft Intune mobile device management console, Handala remotely wiped more than 200,000 devices — including servers, laptops, and mobile devices — across Stryker's global network. The group also claimed to have exfiltrated 50 terabytes of corporate data. The attack began at Stryker's Cork, Ireland headquarters and cascaded across global manufacturing and distribution operations, disrupting order processing, shipping, and production.
The U.S. Federal Bureau of Investigation reportedly seized infrastructure tied to the attack, and at least one lawsuit has been filed related to the data breach.
Q1 2026: The Full Extent of the Damage
The Q1 2026 results quantified the attack's financial toll: - Q1 2026 adjusted EPS: USD 2.60, a decline of 8.5% year-over-year - Q1 2026 revenue fell short of the analyst estimate of USD 6.35B - H1 2026 organic growth compressed to 5.0%, dragged down by Q1 disruption
This stands in sharp contrast to the 17.9% Q2 adjusted EPS growth, illustrating both how severe the Q1 disruption was and how rapidly Stryker recovered its operational footing.
Why Investors Remain Cautious: The H2 Equation
Despite the Q2 recovery, management's guidance commentary flagged that cyber remediation costs and "lost absorption" — the cost of idle manufacturing capacity during the outage — are expected to partially offset tariff relief benefits that Stryker anticipated for H2 2026. This creates a headwind that limits the magnitude of H2 margin recovery.
Three additional factors compound investor caution:
1. MedSurg & Neurotechnology segment miss. The largest segment (USD 3.625B) came in below the estimated USD 3.72B. For a company reporting a headline beat, a miss in the most significant segment is a yellow flag for the robustness of the recovery.
2. Organic growth ceiling reduced. Trimming the top end of the organic growth guidance from 9.5% to 9.3% signals that management does not see sufficient momentum to sustain the upper scenario previously outlined.
3. Inari peripheral vascular disruption. Separately from the cyberattack, Stryker is managing a disruption in its Inari Medical peripheral vascular product line. The conversion of backlog in this category represents an execution risk in H2.
Stock and Valuation Context
At the pre-market price of USD 330.45, the approximately 5.1% decline from the prior close of USD 348.04 erased roughly USD 6.8B in market capitalization in a single session. The sell-off reflects not just the guidance nuances but also the broader question of tail risk from the 50TB data breach: regulatory obligations, potential notification costs, and ongoing litigation remain unquantified.
Medical technology companies typically trade at premium valuation multiples, reflecting predictable recurring revenue from hospital capital budgets and consumables. Uncertainty in the forward earnings picture — whether from cyber incidents, product disruptions, or guidance misses — tends to receive an outsized multiple correction.
For investors monitoring the U.S. medtech sector, Stryker's situation offers a real-world case study in the financial materiality of nation-state cyberattacks. The operational recovery was faster than many expected. The question is whether the financial overhang clears before the premium valuation comes under pressure.
This article is for informational purposes only and does not constitute investment advice.
Sources: - Stryker Q2 2026 Press Release — GlobeNewswire - StockTitan: Stryker Q2 2026 Results - Medical Device Network: Stryker Q2 Revenue USD 6.6B - SecurityWeek: MedTech Giant Stryker Crippled by Iran-Linked Hacker Attack - InfoSecurity Magazine: Iran Claims Massive Cyber-Attack on MedTech Firm Stryker - Seeking Alpha: Stryker FY2026 Guidance Update
